Spots Global Cancer Trial Database for Safety Study of RAD001 to Treat Patients With Metastatic Kidney Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Safety Study of RAD001 to Treat Patients With Metastatic Kidney Cancer
Official Title: Phase II Study of RAD001 (Everolimus) in Patient's With Metastatic Renal Cell Cancer
Study ID: NCT00446368
Conditions
Interventions
Study Description
Brief Summary: Patients with metastatic renal cell cancer will be enrolled to receive RAD001 to determine whether the use of RAD001 will result in an improvement in the time to tumor progression.
Detailed Description: Patients with metastatic renal cell cancer will be enrolled in the study if all eligibility criteria are met and they agree to participate. The participant will take RAD001 (Everolimus) 10mg by mouth once a day. During the first cycle, they will have blood work done once a week (4 weeks). On cycles thereafter they will have blood work on days 7 and 21. Once a month, the patient will have a chest x-ray. Every 8 weeks the patient will have a CT scan of the chest, abdomen and pelvis. If clinically indicated, additional tests will be done.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Baylor College of Medicine - Methodist Hospital, Houston, Texas, United States
Contact Details
Name: Robert J Amato, DO
Affiliation: Baylor College of Medicine - Methodist Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
